Xencor, Inc. (XNCR)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 260
- Market Cap
- $1.6B
About Xencor, Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
SentiSense also tracks daily options readings for Xencor, Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Xencor, Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.